Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Intense Chemotherapy and Stem Cell Rescue in Inflammatory Breast Carcinoma
NCT00003042Phase 2Completed
- Sponsor
- City of Hope
- Start
- May 1997
- Primary completion
- Feb 2010
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin, paclitaxel, cyclophosphamide, melphalan, cisplatin and 2 more in breast cancer (2 arms), sponsored by City of Hope. Primary endpoints: Relapse-free Survival at 3 years and Overall Survival at 5 years. Started May 1997; status: completed.
02
Drugs
doxorubicinpaclitaxelcyclophosphamidemelphalancisplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003042.